454 related articles for article (PubMed ID: 29524560)
1. RAS-mediated oncogenic signaling pathways in human malignancies.
Khan AQ; Kuttikrishnan S; Siveen KS; Prabhu KS; Shanmugakonar M; Al-Naemi HA; Haris M; Dermime S; Uddin S
Semin Cancer Biol; 2019 Feb; 54():1-13. PubMed ID: 29524560
[TBL] [Abstract][Full Text] [Related]
2. Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1.
Lucas L; Penalva V; Ramírez de Molina A; Del Peso L; Lacal JC
Int J Oncol; 2002 Sep; 21(3):477-85. PubMed ID: 12168089
[TBL] [Abstract][Full Text] [Related]
3. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
4. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
Ikenoue T; Hikiba Y; Kanai F; Aragaki J; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
Cancer Res; 2004 May; 64(10):3428-35. PubMed ID: 15150094
[TBL] [Abstract][Full Text] [Related]
5. The impact of oncogenic RAS on redox balance and implications for cancer development.
Lim JKM; Leprivier G
Cell Death Dis; 2019 Dec; 10(12):955. PubMed ID: 31852884
[TBL] [Abstract][Full Text] [Related]
6. Herpesviruses: hijacking the Ras signaling pathway.
Filippakis H; Spandidos DA; Sourvinos G
Biochim Biophys Acta; 2010 Jul; 1803(7):777-85. PubMed ID: 20303365
[TBL] [Abstract][Full Text] [Related]
7. Sec5 and Exo84 foster oncogenic ras-mediated tumorigenesis.
Issaq SH; Lim KH; Counter CM
Mol Cancer Res; 2010 Feb; 8(2):223-31. PubMed ID: 20145037
[TBL] [Abstract][Full Text] [Related]
8. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
9. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
10. Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras.
Vasudevan KM; Burikhanov R; Goswami A; Rangnekar VM
Cancer Res; 2007 Nov; 67(21):10343-50. PubMed ID: 17974977
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation.
Kubota Y; O'Grady P; Saito H; Takekawa M
Nat Cell Biol; 2011 Mar; 13(3):282-91. PubMed ID: 21336309
[TBL] [Abstract][Full Text] [Related]
12. Differential oncogenic Ras signaling and senescence in tumor cells.
Bihani T; Mason DX; Jackson TJ; Chen SC; Boettner B; Lin AW
Cell Cycle; 2004 Sep; 3(9):1201-7. PubMed ID: 15492501
[TBL] [Abstract][Full Text] [Related]
13. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Wong EW; Chang F; Lehmann B; Terrian DM; Milella M; Tafuri A; Stivala F; Libra M; Basecke J; Evangelisti C; Martelli AM; Franklin RA
Biochim Biophys Acta; 2007 Aug; 1773(8):1263-84. PubMed ID: 17126425
[TBL] [Abstract][Full Text] [Related]
14. PI3K: A Crucial Piece in the RAS Signaling Puzzle.
Krygowska AA; Castellano E
Cold Spring Harb Perspect Med; 2018 Jun; 8(6):. PubMed ID: 28847905
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications.
Imperial R; Toor OM; Hussain A; Subramanian J; Masood A
Semin Cancer Biol; 2019 Feb; 54():14-28. PubMed ID: 29175106
[TBL] [Abstract][Full Text] [Related]
16. RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action.
Masliah-Planchon J; Garinet S; Pasmant E
Oncotarget; 2016 Jun; 7(25):38892-38907. PubMed ID: 26646588
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers downstream of RAS: a search for robust transcriptional targets.
Györffy B; Schäfer R
Curr Cancer Drug Targets; 2010 Dec; 10(8):858-68. PubMed ID: 20718707
[TBL] [Abstract][Full Text] [Related]
18. RAS oncogenic signal upregulates EZH2 in pancreatic cancer.
Fujii S; Fukamachi K; Tsuda H; Ito K; Ito Y; Ochiai A
Biochem Biophys Res Commun; 2012 Jan; 417(3):1074-9. PubMed ID: 22222375
[TBL] [Abstract][Full Text] [Related]
19. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
[TBL] [Abstract][Full Text] [Related]
20. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
Moon BS; Jeong WJ; Park J; Kim TI; Min do S; Choi KY
J Natl Cancer Inst; 2014 Feb; 106(2):djt373. PubMed ID: 24491301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
